[go: up one dir, main page]

PT814789E - Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b - Google Patents

Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b

Info

Publication number
PT814789E
PT814789E PT96904929T PT96904929T PT814789E PT 814789 E PT814789 E PT 814789E PT 96904929 T PT96904929 T PT 96904929T PT 96904929 T PT96904929 T PT 96904929T PT 814789 E PT814789 E PT 814789E
Authority
PT
Portugal
Prior art keywords
monoamine
oxidase
inhibitors
pharmaceutical compositions
compositions under
Prior art date
Application number
PT96904929T
Other languages
English (en)
Inventor
Edward Stewart Johnson
Anthony Clarke
Francesca Mary Brewer
Original Assignee
Scherer Technologies Inc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT814789(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9504235.4A external-priority patent/GB9504235D0/en
Application filed by Scherer Technologies Inc R P filed Critical Scherer Technologies Inc R P
Publication of PT814789E publication Critical patent/PT814789E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
PT96904929T 1995-03-02 1996-03-01 Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b PT814789E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9504235.4A GB9504235D0 (en) 1995-03-02 1995-03-02 Pharmaceutical compositon
GBGB9517063.5A GB9517063D0 (en) 1995-03-02 1995-08-18 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
PT814789E true PT814789E (pt) 2003-09-30

Family

ID=26306612

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96904929T PT814789E (pt) 1995-03-02 1996-03-01 Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b

Country Status (26)

Country Link
US (3) US20010021722A1 (pt)
EP (1) EP0814789B2 (pt)
JP (1) JP3273141B2 (pt)
CN (1) CN1171586C (pt)
AT (1) ATE241346T1 (pt)
AU (1) AU702161B2 (pt)
BG (1) BG63862B1 (pt)
BR (1) BR9607057A (pt)
CA (1) CA2214026C (pt)
CZ (1) CZ297382B6 (pt)
DE (1) DE69628415T3 (pt)
DK (1) DK0814789T4 (pt)
EE (1) EE04039B1 (pt)
ES (1) ES2199283T5 (pt)
GE (1) GEP20012374B (pt)
HU (1) HU228852B1 (pt)
IS (1) IS2789B (pt)
MX (1) MX9706647A (pt)
NO (1) NO316804B1 (pt)
NZ (2) NZ302723A (pt)
PL (1) PL183266B1 (pt)
PT (1) PT814789E (pt)
SI (1) SI0814789T2 (pt)
SK (1) SK284383B6 (pt)
TR (1) TR199700878T1 (pt)
WO (1) WO1996026720A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
AU723047B2 (en) 1995-02-10 2000-08-17 University Of Toronto Innovations Foundation, The Deprenyl compounds for treatment of glaucoma
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
JPH11504944A (ja) * 1995-11-06 1999-05-11 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレギリンの舌下およびバッカル投与
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
GB9717770D0 (en) * 1997-08-21 1997-10-29 Scherer Ltd R P Pharmaceutical composition
GB9802088D0 (en) * 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
DE69918339T2 (de) * 1999-04-21 2005-08-25 Yuyu Inc., Anyang Pharmazeutische zusammensetzungen die selegilin und ginkgo biloba extrakt enthalten zur behandlung von demenz
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
ATE521343T1 (de) * 2004-11-24 2011-09-15 Teva Pharma Im mund zerfallende zusammensetzungen von rasagilin
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
CN101262867A (zh) 2005-07-01 2008-09-10 叶林发现公司 用于治疗肥胖的mao-b抑制剂
CN1911211B (zh) * 2006-08-25 2010-04-14 重庆医药工业研究院有限责任公司 雷沙吉兰口服固体制剂
EP1897543A1 (en) * 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20070190187A1 (en) * 2006-09-07 2007-08-16 Kneller Bruce W Formulation for enhanced delivery of phenethylamine
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
MX2011012078A (es) * 2009-05-20 2012-03-14 Lingual Consegna Pty Ltd Formulacion terapeutica bucal y/o sublingual.
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
EP3432931A1 (en) 2016-03-26 2019-01-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositons for n-propargylamine derivative

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) * 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4454158A (en) * 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
IE53696B1 (en) * 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
JP2660419B2 (ja) * 1988-04-02 1997-10-08 旭電化工業株式会社 安定化された合成樹脂組成物
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5192550A (en) † 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
GB9017610D0 (en) * 1990-08-10 1990-09-26 Erba Carlo Spa Antiparkinson mao reversible inhibitor
JP2807346B2 (ja) † 1991-12-24 1998-10-08 山之内製薬株式会社 口腔内崩壊製剤及びその製造法
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
WO1993025197A1 (en) † 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
JPH11504944A (ja) * 1995-11-06 1999-05-11 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレギリンの舌下およびバッカル投与

Also Published As

Publication number Publication date
EE04039B1 (et) 2003-06-16
IS2789B (is) 2012-06-15
JP3273141B2 (ja) 2002-04-08
GEP20012374B (en) 2001-03-25
BG63862B1 (bg) 2003-04-30
AU702161B2 (en) 1999-02-18
WO1996026720A1 (en) 1996-09-06
DE69628415T2 (de) 2004-03-11
NZ329471A (en) 1999-10-28
BG101937A (en) 1998-07-31
CN1171586C (zh) 2004-10-20
PL183266B1 (pl) 2002-06-28
EP0814789B2 (en) 2008-01-09
PL322046A1 (en) 1998-01-05
SK115897A3 (en) 1998-03-04
HU228852B1 (en) 2013-06-28
CZ297382B6 (cs) 2006-11-15
BR9607057A (pt) 1998-06-09
EP0814789B1 (en) 2003-05-28
AU4884696A (en) 1996-09-18
HUP9801227A3 (en) 2000-02-28
NO974010D0 (no) 1997-09-01
CN1178461A (zh) 1998-04-08
US20080187573A1 (en) 2008-08-07
DE69628415T3 (de) 2008-06-26
SI0814789T2 (sl) 2008-04-30
EP0814789A1 (en) 1998-01-07
TR199700878T1 (xx) 1998-01-21
NZ302723A (en) 1998-04-27
NO316804B1 (no) 2004-05-18
EE9700187A (et) 1998-02-16
DK0814789T3 (da) 2003-09-01
ES2199283T3 (es) 2004-02-16
CA2214026A1 (en) 1996-09-06
MX9706647A (es) 1998-06-30
ES2199283T5 (es) 2008-05-16
NO974010L (no) 1997-10-30
HUP9801227A2 (hu) 1999-06-28
CA2214026C (en) 2007-10-16
JPH10506409A (ja) 1998-06-23
SI0814789T1 (en) 2003-12-31
CZ270597A3 (cs) 1998-01-14
DE69628415D1 (de) 2003-07-03
DK0814789T4 (da) 2008-05-19
IS4553A (is) 1997-08-27
SK284383B6 (sk) 2005-02-04
ATE241346T1 (de) 2003-06-15
US20040091525A1 (en) 2004-05-13
US20010021722A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
PT814789E (pt) Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b
ATE525061T1 (de) Feste selbst-haftende zusammensetzungen zur topischen behandlung von störungen der mundschleimhaut
BR9808948A (pt) Composição de confeitaria
ES2103587T3 (es) Composiciones terapeuticas ingeribles, estables y absorbibles de nadh y de nadph.
DE69932864D1 (de) Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
PT706398E (pt) Composicao farmaceutica contendo heparina fragmentos de heparina ou seus derivados em combinacao com esteres de glicerol
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
ATE284690T1 (de) Antithrombotische diamine
DE69802113D1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
NZ513096A (en) Compositions for treating inflammatory response
EA199900876A1 (ru) Фармацевтические композиции против кашля
PT888327E (pt) Derivados de benzopirano que possuem uma accao antagonistica dos leucotrienos
WO2001034172A3 (en) Methods and compositions for treating reward deficiency syndrome
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
BR0212899A (pt) Compostos orgânicos
ATE159511T1 (de) Derivate von n,n,n',n'-tetrasubstituierten 1,2- ethylendiamin-verbindungen
ITMI950132A1 (it) Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
GT199400048A (es) Composicion farmaceutica y proceso para su preparacion
DE602004002718D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Herpes Zoster
MD940244A (ro) Derivaţi noi ai tetrazolului, procedeu de obţinere a lor şi compoziţie farmaceutică pe baza lor
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1